up-to-date with a click!
Update - November 2017
 
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.
The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications November 2017

Other

  1. Brinton EA, Hopkins PN, Hegele RA et al. The association between hypercholesterolemia and sitosterolemia, and report of a sitosterolemia kindred. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29169939
  2. Madasamy S, Liu D, Lundry J et al. Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles. Journal of visualized experiments : JoVE 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29155776
  3. Gnjidic D, Du W, Pearson SA et al. Ascertainment of self-reported prescription medication use compared with pharmaceutical claims data. Public health research & practice 2017; 27. http://www.ncbi.nlm.nih.gov/pubmed/?term=29114718

Add on treatments

  1. Lee HY, Kim SY, Choi KJ et al. A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia. Clinical therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29150250
  2. Suh DC, Griggs SK, Henderson ER et al. Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease. Expert review of pharmacoeconomics & outcomes research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29148854
  3. Kato ET, Cannon CP, Blazing MA et al. Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=29151034
  4. Spannella F, Giulietti F, Balietti P et al. Renin-Angiotensin System Blockers and Statins Are Associated With Lower In-Hospital Mortality in Very Elderly Hypertensives. Journal of the American Medical Directors Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29128438
  5. Song M, Chen FF, Li YH et al. Trimetazidine restores the positive adaptation to exercise training by mitigating statin-induced skeletal muscle injury. Journal of cachexia, sarcopenia and muscle 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29152896
  6. Mizobe T, Nakamura M, Motooka Y et al. Impact of Additional Lipid-Lowering Therapy on New Ischemic Lesions of Diffusion-Weighted Imaging in Carotid Artery Stenting. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29103862
  7. Pascual Fuster V. [Usefulness of plant sterols in the treatment of hypercholesterolemia]. Nutricion hospitalaria 2017; 34:62-67. http://www.ncbi.nlm.nih.gov/pubmed/?term=29156935

Adherence

  1. Bosworth HB, Brown JN, Danus S et al. Evaluation of a packaging approach to improve cholesterol medication adherence. The American journal of managed care 2017; 23:e280-e286. http://www.ncbi.nlm.nih.gov/pubmed/?term=29087166
  2. Eindhoven DC, Hilt AD, Zwaan TC et al. Age and gender differences in medical adherence after myocardial infarction: Women do not receive optimal treatment - The Netherlands claims database. Eur J Prev Cardiol 2017:2047487317744363. http://www.ncbi.nlm.nih.gov/pubmed/?term=29164916
  3. Lucas JE, Bazemore TC, Alo C et al. An electronic health record based model predicts statin adherence, LDL cholesterol, and cardiovascular disease in the United States Military Health System. PLoS One 2017; 12:e0187809. http://www.ncbi.nlm.nih.gov/pubmed/?term=29155848
  4. Soska V, Kyselak O. [Is it possible to improve long-term compliance of patients to statin therapy?]. Vnitr Lek 2017; 63:663-666. http://www.ncbi.nlm.nih.gov/pubmed/?term=29127749

Atherosclerosis & Imaging

  1. Minami Y, Wang Z, Aguirre AD et al. Clinical Predictors for Lack of Favorable Vascular Response to Statin Therapy in Patients With Coronary Artery Disease: A Serial Optical Coherence Tomography Study. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=29092845
  2. Wada S, Koga M, Toyoda K et al. Factors Associated with Intima-Media Complex Thickness of the Common Carotid Artery in Japanese Noncardioembolic Stroke Patients with Hyperlipidemia: The J-STARS Echo Study. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29118311
  3. Mizobe T, Nakamura M, Motooka Y et al. Impact of Additional Lipid-Lowering Therapy on New Ischemic Lesions of Diffusion-Weighted Imaging in Carotid Artery Stenting. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29103862
  4. Michos ED, Blaha MJ, Blumenthal RS. Use of the Coronary Artery Calcium Score in Discussion of Initiation of Statin Therapy in Primary Prevention. Mayo Clinic proceedings 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29108840

Atorvastatin/Rosuvastatin

  1. Yu P, Xiong T, Tenedero CB et al. Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering. Arterioscler Thromb Vasc Biol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29162602
  2. Hoeke G, Wang Y, van Dam AD et al. Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis. Atherosclerosis 2017; 267:116-126. http://www.ncbi.nlm.nih.gov/pubmed/?term=29121499
  3. Kim KM, Jung KY, Yun HM et al. Effect of rosuvastatin on fasting and postprandial endothelial biomarker levels and microvascular reactivity in patients with type 2 diabetes and dyslipidemia: a preliminary report. Cardiovascular diabetology 2017; 16:146. http://www.ncbi.nlm.nih.gov/pubmed/?term=29121934
  4. Chen S, Dong S, Li Z et al. Atorvastatin Calcium Inhibits PDGF-betabeta-Induced Proliferation and Migration of VSMCs Through the G0/G1 Cell Cycle Arrest and Suppression of Activated PDGFRbeta-PI3K-Akt Signaling Cascade. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2017; 44:215-228. http://www.ncbi.nlm.nih.gov/pubmed/?term=29131001
  5. Burstein B, Altobelli KK, Williams K et al. Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey. Circulation 2017; 136:1860-1862. http://www.ncbi.nlm.nih.gov/pubmed/?term=29109198
  6. Lee HY, Kim SY, Choi KJ et al. A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia. Clinical therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29150250
  7. Ishida K, Ullah M, Toth B et al. Successful prediction of in vivo hepatobiliary clearances and hepatic concentrations of rosuvastatin using sandwich-cultured rat hepatocytes, transporter-expressing cell lines, and quantitative proteomics. Drug metabolism and disposition: the biological fate of chemicals 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29084782
  8. Bishnu S, Ahammed SM, Sarkar A et al. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study. European journal of gastroenterology & hepatology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29099421
  9. Krysiak R, Szkrobka W, Okopien B. The Effect of Hypolipidemic Agents on Thyroid Autoimmunity in Women with Hashimoto's Thyroiditis Treated with Levothyroxine and Selenomethionine. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29117614
  10. Suh DC, Griggs SK, Henderson ER et al. Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease. Expert review of pharmacoeconomics & outcomes research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29148854
  11. Abd El-Aal SA, Abd El-Fattah MA, El-Abhar HS. CoQ10 Augments Rosuvastatin Neuroprotective Effect in a Model of Global Ischemia via Inhibition of NF-kappaB/JNK3/Bax and Activation of Akt/FOXO3A/Bim Cues. Frontiers in pharmacology 2017; 8:735. http://www.ncbi.nlm.nih.gov/pubmed/?term=29081748
  12. Chang WL, Jackson C, Riel S et al. Differential preventive activity of sulindac and atorvastatin in Apc+/Min-FCCCmice with or without colorectal adenomas. Gut 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29122850
  13. Singh RK, Agarwal V, Baronia AK et al. The Effects of Atorvastatin on Inflammatory Responses and Mortality in Septic Shock: A Single-center, Randomized Controlled Trial. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine 2017; 21:646-654. http://www.ncbi.nlm.nih.gov/pubmed/?term=29142375
  14. Kang WY, Seong SJ, Ohk B et al. Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects. International journal of clinical pharmacology and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29162214
  15. Chang Y, Li Y, Ye N et al. Atorvastatin protects the proliferative ability of human umbilical vein endothelial cells inhibited by angiotensin II by changing mitochondrial energy metabolism. International journal of molecular medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29115384
  16. Sadak KT, Marlatt KL. Re: "The Effect of Atorvastatin on Vascular Function and Structure in Young Adult Survivors of Childhood Cancer: A Randomized, Placebo-Controlled Pilot Clinical Trial" by Marlatt et al. (J Adolesc Young Adult Oncol. 2017 [Epub ahead of print]; DOI: 10.1089/jayao.2017.0075). Journal of adolescent and young adult oncology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29099645
  17. Arsenault BJ, Petrides F, Tabet F et al. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29103916
  18. Kirzioglu FY, Ozmen O, Dogan B et al. Effects of rosuvastatin on inducible nitric oxide synthase in rats with hyperlipidaemia and periodontitis. Journal of periodontal research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29086411
  19. Beavers JC. Elevated Creatine Kinase due to Potential Drug Interaction With Ticagrelor and Atorvastatin. Journal of pharmacy practice 2017:897190017740282. http://www.ncbi.nlm.nih.gov/pubmed/?term=29096571
  20. Schwinte P, Mariotte A, Anand P et al. Anti-inflammatory effect of active nanofibrous polymeric membrane bearing nanocontainers of atorvastatin complexes. Nanomedicine (Lond) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29094650
  21. Marques NF, Castro AA, Mancini G et al. Atorvastatin Prevents Early Oxidative Events and Modulates Inflammatory Mediators in the Striatum Following Intranasal 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Administration in Rats. Neurotox Res 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29164519
  22. Pauchard LA, Blot M, Bruyere R et al. Linezolid and atorvastatin impact on pneumonia caused by Staphyloccocus aureus in rabbits with or without mechanical ventilation. PLoS One 2017; 12:e0187187. http://www.ncbi.nlm.nih.gov/pubmed/?term=29149185
  23. Maki K, Diwadkar-Navsariwala V, Kramer MW. Statin use and risk for type 2 diabetes: what clinicians should know. Postgraduate medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29139315

Basic science

  1. Yao H, Lv J. Statin Attenuated Myocardial Inflammation Induced by PM2.5 in Rats. Acta Cardiologica Sinica 2017; 33:637-645. http://www.ncbi.nlm.nih.gov/pubmed/?term=29167617
  2. Leenders GJ, Smeets MB, van den Boomen M et al. Statins Promote Cardiac Infarct Healing by Modulating Endothelial Barrier Function Revealed by Contrast-Enhanced Magnetic Resonance Imaging. Arterioscler Thromb Vasc Biol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29146749
  3. Yu P, Xiong T, Tenedero CB et al. Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering. Arterioscler Thromb Vasc Biol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29162602
  4. Hoeke G, Wang Y, van Dam AD et al. Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis. Atherosclerosis 2017; 267:116-126. http://www.ncbi.nlm.nih.gov/pubmed/?term=29121499
  5. Raghu VK, Beckwitt CH, Warita K et al. Biomarker identification for statin sensitivity of cancer cell lines. Biochem Biophys Res Commun 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29146185
  6. Chen S, Dong S, Li Z et al. Atorvastatin Calcium Inhibits PDGF-betabeta-Induced Proliferation and Migration of VSMCs Through the G0/G1 Cell Cycle Arrest and Suppression of Activated PDGFRbeta-PI3K-Akt Signaling Cascade. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2017; 44:215-228. http://www.ncbi.nlm.nih.gov/pubmed/?term=29131001
  7. Sarfraz RM, Ahmad M, Mahmood A et al. Development of beta-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation. Drug design, development and therapy 2017; 11:3083-3096. http://www.ncbi.nlm.nih.gov/pubmed/?term=29123380
  8. Ishida K, Ullah M, Toth B et al. Successful prediction of in vivo hepatobiliary clearances and hepatic concentrations of rosuvastatin using sandwich-cultured rat hepatocytes, transporter-expressing cell lines, and quantitative proteomics. Drug metabolism and disposition: the biological fate of chemicals 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29084782
  9. Salama AH, Basha M, El Awdan S. Experimentally designed lyophilized dry emulsion tablets for enhancing the antihyperlipidemic activity of atorvastatin calcium: Preparation, in-vitro evaluation and in-vivo assessment. Eur J Pharm Sci 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29117504
  10. Nozu T, Miyagishi S, Kumei S et al. Lovastatin inhibits visceral allodynia and increased colonic permeability induced by lipopolysaccharide or repeated water avoidance stress in rats. Eur J Pharmacol 2017; 818:228-234. http://www.ncbi.nlm.nih.gov/pubmed/?term=29107672
  11. Li H, Zhao Q, Liu R et al. Protective Effect and Potential Mechanism of Simvastatin on Myocardial Injury Induced by Diabetes with Hypoglycemia. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29165724
  12. Abd El-Aal SA, Abd El-Fattah MA, El-Abhar HS. CoQ10 Augments Rosuvastatin Neuroprotective Effect in a Model of Global Ischemia via Inhibition of NF-kappaB/JNK3/Bax and Activation of Akt/FOXO3A/Bim Cues. Frontiers in pharmacology 2017; 8:735. http://www.ncbi.nlm.nih.gov/pubmed/?term=29081748
  13. Chang WL, Jackson C, Riel S et al. Differential preventive activity of sulindac and atorvastatin in Apc+/Min-FCCCmice with or without colorectal adenomas. Gut 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29122850
  14. Akarsu M, Saygun O, Aydinuraz K et al. The Effects of Simvastatin on Ischemia Reperfusion Injury in an Experimental Colon Anastomosis Model. The Indian journal of surgery 2017; 79:390-395. http://www.ncbi.nlm.nih.gov/pubmed/?term=29089696
  15. Kang WY, Seong SJ, Ohk B et al. Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects. International journal of clinical pharmacology and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29162214
  16. Chang Y, Li Y, Ye N et al. Atorvastatin protects the proliferative ability of human umbilical vein endothelial cells inhibited by angiotensin II by changing mitochondrial energy metabolism. International journal of molecular medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29115384
  17. Lee JY, Kim MS, Ju JE et al. Simvastatin enhances the radiosensitivity of p53deficient cells via inhibition of mouse double minute 2 homolog. International journal of oncology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29115437
  18. Karaji ZG, Houshmand B, Abbasi S et al. Biofunctionalization of Titanium Granules with Simvastatin for Improving Osteogenic Activity and Antibacterial Properties (Ex Vivo Study). The International journal of oral & maxillofacial implants 2017; 32:1266-1272. http://www.ncbi.nlm.nih.gov/pubmed/?term=29140371
  19. Song M, Chen FF, Li YH et al. Trimetazidine restores the positive adaptation to exercise training by mitigating statin-induced skeletal muscle injury. Journal of cachexia, sarcopenia and muscle 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29152896
  20. Kirzioglu FY, Ozmen O, Dogan B et al. Effects of rosuvastatin on inducible nitric oxide synthase in rats with hyperlipidaemia and periodontitis. Journal of periodontal research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29086411
  21. Madasamy S, Liu D, Lundry J et al. Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles. Journal of visualized experiments : JoVE 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29155776
  22. Schwinte P, Mariotte A, Anand P et al. Anti-inflammatory effect of active nanofibrous polymeric membrane bearing nanocontainers of atorvastatin complexes. Nanomedicine (Lond) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29094650
  23. Chung L, Bey AL, Towers AJ et al. Lovastatin suppresses hyperexcitability and seizure in Angelman syndrome model. Neurobiology of disease 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29097328
  24. Marques NF, Castro AA, Mancini G et al. Atorvastatin Prevents Early Oxidative Events and Modulates Inflammatory Mediators in the Striatum Following Intranasal 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Administration in Rats. Neurotox Res 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29164519
  25. Buranrat B, Suwannaloet W, Naowaboot J. Simvastatin potentiates doxorubicin activity against MCF-7 breast cancer cells. Oncology letters 2017; 14:6243-6250. http://www.ncbi.nlm.nih.gov/pubmed/?term=29113274
  26. Wang Q, Yang YB, Yang XQ et al. Lovastatin analogues and other metabolites from soil-derived Aspergillus terreus YIM PH30711. Phytochemistry 2017; 145:146-152. http://www.ncbi.nlm.nih.gov/pubmed/?term=29132077
  27. Pauchard LA, Blot M, Bruyere R et al. Linezolid and atorvastatin impact on pneumonia caused by Staphyloccocus aureus in rabbits with or without mechanical ventilation. PLoS One 2017; 12:e0187187. http://www.ncbi.nlm.nih.gov/pubmed/?term=29149185
  28. Porfire A, Muntean DM, Rus L et al. A quality by design approach for the development of lyophilized liposomes with simvastatin. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society 2017; 25:981-992. http://www.ncbi.nlm.nih.gov/pubmed/?term=29158704

Cancer

  1. Raghu VK, Beckwitt CH, Warita K et al. Biomarker identification for statin sensitivity of cancer cell lines. Biochem Biophys Res Commun 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29146185
  2. Kawaguchi Y, Sakamoto Y, Ito D et al. Statin use is associated with a reduced risk of hepatocellular carcinoma recurrence after initial liver resection. Bioscience trends 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29081488
  3. Kang M, Ku JH, Kwak C et al. Effects of Aspirin, Nonsteroidal Anti-inflammatory Drugs, Statin and COX2 Inhibitor on the Developments of Urological Malignancies: A Population-Based Study with 10-Year Follow-up Data in Korea. Cancer research and treatment : official journal of Korean Cancer Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29081218
  4. Orho-Melander M, Hindy G, Borgquist S et al. Blood lipid genetic scores, the HMGCR gene and cancer risk: a Mendelian randomization study. International journal of epidemiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29165714
  5. Sadak KT, Marlatt KL. Re: "The Effect of Atorvastatin on Vascular Function and Structure in Young Adult Survivors of Childhood Cancer: A Randomized, Placebo-Controlled Pilot Clinical Trial" by Marlatt et al. (J Adolesc Young Adult Oncol. 2017 [Epub ahead of print]; DOI: 10.1089/jayao.2017.0075). Journal of adolescent and young adult oncology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29099645
  6. Kim G, Jang SY, Nam CM, Kang ES. Statin use and the risk of hepatocellular carcinoma in patients at high risk: a nationwide nested case-control study. J Hepatol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29107150
  7. Buranrat B, Suwannaloet W, Naowaboot J. Simvastatin potentiates doxorubicin activity against MCF-7 breast cancer cells. Oncology letters 2017; 14:6243-6250. http://www.ncbi.nlm.nih.gov/pubmed/?term=29113274
  8. Yang K, Marley A, Tang H et al. Statin use and non-melanoma skin cancer risk: a meta-analysis of randomized controlled trials and observational studies. Oncotarget 2017; 8:75411-75417. http://www.ncbi.nlm.nih.gov/pubmed/?term=29088876
  9. Nishio T, Taura K, Nakamura N et al. Impact of statin use on the prognosis of patients with hepatocellular carcinoma undergoing liver resection: a subgroup analysis of patients without chronic hepatitis viral infection. Surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29167018

Children

  1. Brinton EA, Hopkins PN, Hegele RA et al. The association between hypercholesterolemia and sitosterolemia, and report of a sitosterolemia kindred. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29169939
  2. Marcovecchio ML, Chiesa ST, Bond S et al. ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. N Engl J Med 2017; 377:1733-1745. http://www.ncbi.nlm.nih.gov/pubmed/?term=29091568

Cost-effectiveness

  1. Suh DC, Griggs SK, Henderson ER et al. Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease. Expert review of pharmacoeconomics & outcomes research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29148854
  2. Kodera S, Kiyosue A, Ando J et al. Cost-Effectiveness Analysis of Cardiovascular Disease Treatment in Japan. Int Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29151496

CVD

  1. Waldeyer C, Seiffert M, Staebe N et al. Lipid Management After First Diagnosis of Coronary Artery Disease: Contemporary Results From an Observational Cohort Study. Clinical therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29103665
  2. Wakabayashi K, Ikeda N, Kajimoto K et al. Trends and predictors of non-cardiovascular death in patients hospitalized for acute heart failure. Int J Cardiol 2018; 250:164-170. http://www.ncbi.nlm.nih.gov/pubmed/?term=29169753
  3. Cho J, Park IB, Lee K et al. Statin has more protective effects in AMI patients with higher plasma BNP or NT-proBNP level, but not with lower left ventricular ejection fraction. J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29158023
  4. Storey BC, Staplin N, Haynes R et al. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney international 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29146277
  5. Xie S, Zhou J. Effect of statins and the clinical nursing characteristics in patients with acute myocardial infarction. Pak J Pharm Sci 2017; 30:1843-1849. http://www.ncbi.nlm.nih.gov/pubmed/?term=29084656
  6. Parikh KH, Kirtane AJ. Should We Up the Intensity of Statin Therapy After Placing a Drug-eluting Stent. Rev Esp Cardiol (Engl Ed) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29104001 

Endothelium/inflammation

  1. Yao H, Lv J. Statin Attenuated Myocardial Inflammation Induced by PM2.5 in Rats. Acta Cardiologica Sinica 2017; 33:637-645. http://www.ncbi.nlm.nih.gov/pubmed/?term=29167617
  2. Kim KM, Jung KY, Yun HM et al. Effect of rosuvastatin on fasting and postprandial endothelial biomarker levels and microvascular reactivity in patients with type 2 diabetes and dyslipidemia: a preliminary report. Cardiovascular diabetology 2017; 16:146. http://www.ncbi.nlm.nih.gov/pubmed/?term=29121934
  3. Singh RK, Agarwal V, Baronia AK et al. The Effects of Atorvastatin on Inflammatory Responses and Mortality in Septic Shock: A Single-center, Randomized Controlled Trial. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine 2017; 21:646-654. http://www.ncbi.nlm.nih.gov/pubmed/?term=29142375
  4. Sandesara PB, Ramjee V, Ghasemzadeh N et al. Circulating progenitor cells in patients with familial hypercholesterolemia. Journal of clinical apheresis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29114919
  5. Schwinte P, Mariotte A, Anand P et al. Anti-inflammatory effect of active nanofibrous polymeric membrane bearing nanocontainers of atorvastatin complexes. Nanomedicine (Lond) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29094650
  6. Pauchard LA, Blot M, Bruyere R et al. Linezolid and atorvastatin impact on pneumonia caused by Staphyloccocus aureus in rabbits with or without mechanical ventilation. PLoS One 2017; 12:e0187187. http://www.ncbi.nlm.nih.gov/pubmed/?term=29149185

Ethnicity

  1. Hwong WY, Abdul Aziz Z, Sidek NN et al. Prescription of secondary preventive drugs after ischemic stroke: results from the Malaysian National Stroke Registry. BMC Neurol 2017; 17:203. http://www.ncbi.nlm.nih.gov/pubmed/?term=29169331
  2. Lumu W, Kampiire L, Akabwai GP et al. Dyslipidaemia in a Black African diabetic population: burden, pattern and predictors. BMC research notes 2017; 10:587. http://www.ncbi.nlm.nih.gov/pubmed/?term=29121994
  3. Koh KK, Nam CW, Chao TH et al. A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT). J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29153823
  4. Zheng W, Zhang YJ, Bu XT et al. LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China: Subgroup analysis of the dyslipidemia international study of China (DYSIS-China). Medicine (Baltimore) 2017; 96:e8555. http://www.ncbi.nlm.nih.gov/pubmed/?term=29145263

FH

  1. Stefanutti C, Mazza F, Mesce D et al. Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: A clinical study. Atherosclerosis. Supplements 2017; 30:86-91. http://www.ncbi.nlm.nih.gov/pubmed/?term=29096866
  2. Stefanutti C, Mazza F, Mesce D et al. Corrigendum to "Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: A clinical study" [Atherosclerosis (Supplements) 30C (2017) 86-91]. Atherosclerosis. Supplements 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29153764
  3. Watson KE, Fonarow GC. Closing the Remaining Evidence Gap: Randomized Controlled Trial Data to Support Statin Therapy for Low-Density Lipoprotein >/=190 mg/dL. Circulation 2017; 136:1892-1894. http://www.ncbi.nlm.nih.gov/pubmed/?term=29133529
  4. Thompson GR, Blom DJ, Marais AD et al. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29106543
  5. Sandesara PB, Ramjee V, Ghasemzadeh N et al. Circulating progenitor cells in patients with familial hypercholesterolemia. Journal of clinical apheresis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29114919
  6. Brinton EA, Hopkins PN, Hegele RA et al. The association between hypercholesterolemia and sitosterolemia, and report of a sitosterolemia kindred. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29169939
  7. Sun D, Li S, Zhao X et al. Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: a case control study. Metabolism 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29129821
  8. Auckle R, Su B, Li H et al. Familial hypercholesterolemia in Chinese patients with premature ST-segment-elevation myocardial infarction: Prevalence, lipid management and 1-year follow-up. PLoS One 2017; 12:e0186815. http://www.ncbi.nlm.nih.gov/pubmed/?term=29088271

Generics

  1. Alatawi Y, Rahman MM, Cheng N et al. Brand vs generic adverse event reporting patterns: An authorized generic-controlled evaluation of cardiovascular medications. Journal of clinical pharmacy and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29092097

Genetics

  1. Kirac D, Bayam E, Dagdelen M et al. HMGCR and ApoE mutations may cause different responses to lipid lowering statin therapy. Cell Mol Biol (Noisy-le-grand) 2017; 63:43-48. http://www.ncbi.nlm.nih.gov/pubmed/?term=29096742
  2. Orho-Melander M, Hindy G, Borgquist S et al. Blood lipid genetic scores, the HMGCR gene and cancer risk: a Mendelian randomization study. International journal of epidemiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29165714
Guidelines
  1. Navar AM, Wang TY, Li S et al. Lipid management in contemporary community practice: Results from the Provider Assessment of Lipid Management (PALM) Registry. Am Heart J 2017; 193:84-92. http://www.ncbi.nlm.nih.gov/pubmed/?term=29129260
  2. Cascino T, Vali M, Redberg R et al. Guideline concordance of new statin prescriptions: who got a statin? The American journal of managed care 2017; 23:528-533. http://www.ncbi.nlm.nih.gov/pubmed/?term=29087155
  3. Shen X, Stuart BC, Powers CA et al. Impact of formulary restrictions on medication use and costs. The American journal of managed care 2017; 23:e265-e274. http://www.ncbi.nlm.nih.gov/pubmed/?term=29087150
  4. Cheng-Lai A, Snead J, Ng C et al. Comparison of Adherence to the 2013 ACC/AHA Cholesterol Guideline in a Teaching Versus Nonteaching Outpatient Clinic. The Annals of pharmacotherapy 2017:1060028017739325. http://www.ncbi.nlm.nih.gov/pubmed/?term=29103310
  5. Brown F, Singer A, Katz A, Konrad G. Statin-prescribing trends for primary and secondary prevention of cardiovascular disease. Canadian family physician Medecin de famille canadien 2017; 63:e495-e503. http://www.ncbi.nlm.nih.gov/pubmed/?term=29138175
  6. Pavlovic J, Greenland P, Deckers JW et al. Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease based on available randomised clinical trial evidence: The Rotterdam Study. Eur J Prev Cardiol 2017:2047487317743352. http://www.ncbi.nlm.nih.gov/pubmed/?term=29171772
  7. Markovitz AA, Holleman RG, Hofer TP et al. Effects of Guideline and Formulary Changes on Statin Prescribing in the Veterans Affairs. Health services research 2017; 52:1996-2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29130272
  8. Espinola-Klein C. [ESC guidelines 2017 on peripheral arterial diseases : Summary of the most important recommendations and innovations]. Herz 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29143147
  9. Singh A, Collins BL, Gupta A et al. Cardiovascular Risk and Statin Eligibility of Young Adults After an Myocardial Infarction: Partners YOUNG-MI Registry. J Am Coll Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29141201
  10. Michos ED, Blaha MJ, Blumenthal RS. Use of the Coronary Artery Calcium Score in Discussion of Initiation of Statin Therapy in Primary Prevention. Mayo Clinic proceedings 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29108840
  11. Zheng W, Zhang YJ, Bu XT et al. LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China: Subgroup analysis of the dyslipidemia international study of China (DYSIS-China). Medicine (Baltimore) 2017; 96:e8555. http://www.ncbi.nlm.nih.gov/pubmed/?term=29145263

LDL- related parameters

  1. Kirac D, Bayam E, Dagdelen M et al. HMGCR and ApoE mutations may cause different responses to lipid lowering statin therapy. Cell Mol Biol (Noisy-le-grand) 2017; 63:43-48. http://www.ncbi.nlm.nih.gov/pubmed/?term=29096742
  2. Waldeyer C, Seiffert M, Staebe N et al. Lipid Management After First Diagnosis of Coronary Artery Disease: Contemporary Results From an Observational Cohort Study. Clinical therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29103665
  3. Zheng W, Zhang YJ, Bu XT et al. LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China: Subgroup analysis of the dyslipidemia international study of China (DYSIS-China). Medicine (Baltimore) 2017; 96:e8555. http://www.ncbi.nlm.nih.gov/pubmed/?term=29145263

Lifestyle

  1. Vaidean GD, Manczuk M, Vansal SS, Griffith J. The cholesterol-lowering effect of statins is potentiated by whole grains intake. The Polish Norwegian Study (PONS). Eur J Intern Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29137927
  2. Choi HK, Hwang JT, Nam TG et al. Welsh onion extract inhibits PCSK9 expression contributing to the maintenance of the LDLR level under lipid depletion conditions of HepG2 cells. Food & function 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29130084

Meta-analyses

  1. Elgendy AY, Elgendy IY, Mahmoud AN et al. Statin Use in Men and New Onset of Erectile Dysfunction: a Systematic Review and Meta-Analysis. Am J Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29146233
  2. Wang Y, Zhu S, Du R et al. Statin initiation and renal outcomes following isolated coronary artery bypass grafting: a meta-analysis. J Cardiovasc Surg (Torino) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29145723
  3. Akram Z, Vohra F, Javed F. Efficacy of statin delivery as an adjunct to scaling and root planing in the treatment of chronic periodontitis: A meta-analysis. Journal of investigative and clinical dentistry 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29119729
  4. Yang K, Marley A, Tang H et al. Statin use and non-melanoma skin cancer risk: a meta-analysis of randomized controlled trials and observational studies. Oncotarget 2017; 8:75411-75417. http://www.ncbi.nlm.nih.gov/pubmed/?term=29088876

Metabolic Syndrome - Diabetes

  1. Marcovecchio ML, Chiesa ST, Bond S et al. ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. N Engl J Med 2017; 377:1733-1745. http://www.ncbi.nlm.nih.gov/pubmed/?term=29091568
  2. Brennan MB, Huang ES, Lobo JM et al. Longitudinal trends and predictors of statin use among patients with diabetes. Journal of diabetes and its complications 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29107453
  3. Kim KM, Jung KY, Yun HM et al. Effect of rosuvastatin on fasting and postprandial endothelial biomarker levels and microvascular reactivity in patients with type 2 diabetes and dyslipidemia: a preliminary report. Cardiovascular diabetology 2017; 16:146. http://www.ncbi.nlm.nih.gov/pubmed/?term=29121934

New Treatments

  1. Wallemacq C. [Evolocumab (Repatha(R)) : a human monoclonal antibody against PCSK9 protein as potent cholesterol-lowering therapy]. Revue medicale de Liege 2017; 72:505-512. http://www.ncbi.nlm.nih.gov/pubmed/?term=29171950
  2. Giugliano RP, Keech A, Murphy SA et al. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29117276
  3. Mizobe T, Nakamura M, Motooka Y et al. Impact of Additional Lipid-Lowering Therapy on New Ischemic Lesions of Diffusion-Weighted Imaging in Carotid Artery Stenting. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29103862
  4. Koh KK, Nam CW, Chao TH et al. A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT). J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29153823
  5. Arsenault BJ, Petrides F, Tabet F et al. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29103916
  6. Gencer B, Koskinas KC, Raber L et al. Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=29122809
  7. Kodera S, Kiyosue A, Ando J et al. Cost-Effectiveness Analysis of Cardiovascular Disease Treatment in Japan. Int Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29151496
  8. Suh DC, Griggs SK, Henderson ER et al. Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease. Expert review of pharmacoeconomics & outcomes research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29148854
  9. Farnier M. Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review. Expert Rev Cardiovasc Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29171769
  10. Hess GP, Natarajan P, Faridi KF et al. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29084735
  11. Bonaca MP, Nault P, Giugliano RP et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29133605
  12. Hess CN, Low Wang CC, Hiatt WR. PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes. Annual review of medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29095667

PAD and statins

  1. Espinola-Klein C. [ESC guidelines 2017 on peripheral arterial diseases : Summary of the most important recommendations and innovations]. Herz 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29143147
  2. Bonaca MP, Nault P, Giugliano RP et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29133605

Pleiotropic effects of statins

  1. Madi M, Kassem A. Topical simvastatin gel as a novel therapeutic modality for palatal donor site wound healing following free gingival graft procedure. Acta odontologica Scandinavica 2017:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=29145771
  2. Labos C, Brophy JM, Smith GD et al. Evaluation of the Pleiotropic Effects of Statins: A Reanalysis of the Randomized Trial Evidence Using Egger Regression. Arterioscler Thromb Vasc Biol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29122815
  3. Leenders GJ, Smeets MB, van den Boomen M et al. Statins Promote Cardiac Infarct Healing by Modulating Endothelial Barrier Function Revealed by Contrast-Enhanced Magnetic Resonance Imaging. Arterioscler Thromb Vasc Biol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29146749
  4. Hoeke G, Wang Y, van Dam AD et al. Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis. Atherosclerosis 2017; 267:116-126. http://www.ncbi.nlm.nih.gov/pubmed/?term=29121499
  5. Kawaguchi Y, Sakamoto Y, Ito D et al. Statin use is associated with a reduced risk of hepatocellular carcinoma recurrence after initial liver resection. Bioscience trends 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29081488
  6. Lee MG, Lee CC, Lai CC et al. Preadmission statin use improves the outcome of less severe sepsis patients - a population-based propensity score matched cohort study. British journal of anaesthesia 2017; 119:645-654. http://www.ncbi.nlm.nih.gov/pubmed/?term=29121292
  7. Saasouh W, Leung S, Yilmaz HO et al. Are perioperative therapeutic doses of statins associated with postoperative pain and opioid consumption after hip surgery under spinal anaesthesia? British journal of anaesthesia 2017; 119:803-811. http://www.ncbi.nlm.nih.gov/pubmed/?term=29121296
  8. Szczepanik A, Hulbert A, Lee HJ et al. Effect of HMG CoA reductase inhibitors on the development of chronic lung allograft dysfunction. Clinical transplantation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29151274
  9. Aktas S, Ucak S, Kurt F et al. Evaluation of protein c and protein s levels in patients with diabetes mellitus receiving therapy with statins and ace inhibitors or angiotensin II receptor blockers. Diabetes Res Clin Pract 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29155121
  10. Bishnu S, Ahammed SM, Sarkar A et al. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study. European journal of gastroenterology & hepatology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29099421
  11. Nozu T, Miyagishi S, Kumei S et al. Lovastatin inhibits visceral allodynia and increased colonic permeability induced by lipopolysaccharide or repeated water avoidance stress in rats. Eur J Pharmacol 2017; 818:228-234. http://www.ncbi.nlm.nih.gov/pubmed/?term=29107672
  12. Li H, Zhao Q, Liu R et al. Protective Effect and Potential Mechanism of Simvastatin on Myocardial Injury Induced by Diabetes with Hypoglycemia. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29165724
  13. Singh RK, Agarwal V, Baronia AK et al. The Effects of Atorvastatin on Inflammatory Responses and Mortality in Septic Shock: A Single-center, Randomized Controlled Trial. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine 2017; 21:646-654. http://www.ncbi.nlm.nih.gov/pubmed/?term=29142375
  14. Zhao Q, Shan W, Liu L et al. Predictors of functional outcome and hemorrhagic complications in acute ischemic stroke patients treated with intravenous thrombolysis - A retrospective analysis. International journal of clinical pharmacology and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29092734
  15. Lee PJ, Modha K, Chua T et al. Association of Statins With Decreased Acute Pancreatitis Severity: A Propensity Score Analysis. Journal of clinical gastroenterology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29095423
  16. Kim G, Jang SY, Nam CM, Kang ES. Statin use and the risk of hepatocellular carcinoma in patients at high risk: a nationwide nested case-control study. J Hepatol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29107150
  17. Akram Z, Vohra F, Javed F. Efficacy of statin delivery as an adjunct to scaling and root planing in the treatment of chronic periodontitis: A meta-analysis. Journal of investigative and clinical dentistry 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29119729
  18. Kirzioglu FY, Ozmen O, Dogan B et al. Effects of rosuvastatin on inducible nitric oxide synthase in rats with hyperlipidaemia and periodontitis. Journal of periodontal research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29086411
  19. Brar S, Ye F, James M et al. Statin Use and Survival After Acute Kidney Injury. Kidney international reports 2016; 1:279-287. http://www.ncbi.nlm.nih.gov/pubmed/?term=29142930
  20. Nahar D. Prophylactic Management of Contrast-Induced Acute Kidney Injury in High-Risk Patients. Nephrology nursing journal : journal of the American Nephrology Nurses' Association 2017; 44:244-249. http://www.ncbi.nlm.nih.gov/pubmed/?term=29165956
  21. Chung L, Bey AL, Towers AJ et al. Lovastatin suppresses hyperexcitability and seizure in Angelman syndrome model. Neurobiology of disease 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29097328
  22. Marques NF, Castro AA, Mancini G et al. Atorvastatin Prevents Early Oxidative Events and Modulates Inflammatory Mediators in the Striatum Following Intranasal 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Administration in Rats. Neurotox Res 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29164519
  23. Al-Rasheed NM, Al-Rasheed NM, Hasan IH et al. Simvastatin Ameliorates Diabetic Cardiomyopathy by Attenuating Oxidative Stress and Inflammation in Rats. Oxidative medicine and cellular longevity 2017; 2017:1092015. http://www.ncbi.nlm.nih.gov/pubmed/?term=29138670
  24. Ko HHT, Lareu RR, Dix BR, Hughes JD. Statins: antimicrobial resistance breakers or makers? PeerJ 2017; 5:e3952. http://www.ncbi.nlm.nih.gov/pubmed/?term=29085751
  25. Pauchard LA, Blot M, Bruyere R et al. Linezolid and atorvastatin impact on pneumonia caused by Staphyloccocus aureus in rabbits with or without mechanical ventilation. PLoS One 2017; 12:e0187187. http://www.ncbi.nlm.nih.gov/pubmed/?term=29149185
  26. Nishio T, Taura K, Nakamura N et al. Impact of statin use on the prognosis of patients with hepatocellular carcinoma undergoing liver resection: a subgroup analysis of patients without chronic hepatitis viral infection. Surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29167018

Primary Prevention

  1. Burstein B, Altobelli KK, Williams K et al. Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey. Circulation 2017; 136:1860-1862. http://www.ncbi.nlm.nih.gov/pubmed/?term=29109198
  2. Pavlovic J, Greenland P, Deckers JW et al. Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease based on available randomised clinical trial evidence: The Rotterdam Study. Eur J Prev Cardiol 2017:2047487317743352. http://www.ncbi.nlm.nih.gov/pubmed/?term=29171772
  3. Michos ED, Blaha MJ, Blumenthal RS. Use of the Coronary Artery Calcium Score in Discussion of Initiation of Statin Therapy in Primary Prevention. Mayo Clinic proceedings 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29108840

Registry data

  1. Gulliford M, Ravindrarajah R, Hamada S et al. Inception and deprescribing of statins in people aged over 80 years: cohort study. Age and ageing 2017; 46:1001-1005. http://www.ncbi.nlm.nih.gov/pubmed/?term=29088364
  2. Navar AM, Wang TY, Li S et al. Lipid management in contemporary community practice: Results from the Provider Assessment of Lipid Management (PALM) Registry. Am Heart J 2017; 193:84-92. http://www.ncbi.nlm.nih.gov/pubmed/?term=29129260
  3. Krafcik BM, Farber A, Eberhardt RT et al. Preoperative antiplatelet and statin use does not affect outcomes after carotid endarterectomy. Annals of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29100876
  4. Crandall JP, Mather K, Rajpathak SN et al. Statin use and risk of developing diabetes: results from the Diabetes Prevention Program. BMJ open diabetes research & care 2017; 5:e000438. http://www.ncbi.nlm.nih.gov/pubmed/?term=29081977
  5. Lee MG, Lee CC, Lai CC et al. Preadmission statin use improves the outcome of less severe sepsis patients - a population-based propensity score matched cohort study. British journal of anaesthesia 2017; 119:645-654. http://www.ncbi.nlm.nih.gov/pubmed/?term=29121292
  6. Saasouh W, Leung S, Yilmaz HO et al. Are perioperative therapeutic doses of statins associated with postoperative pain and opioid consumption after hip surgery under spinal anaesthesia? British journal of anaesthesia 2017; 119:803-811. http://www.ncbi.nlm.nih.gov/pubmed/?term=29121296
  7. Brown F, Singer A, Katz A, Konrad G. Statin-prescribing trends for primary and secondary prevention of cardiovascular disease. Canadian family physician Medecin de famille canadien 2017; 63:e495-e503. http://www.ncbi.nlm.nih.gov/pubmed/?term=29138175
  8. Smith I, Schmidt R, Halm EA, Mansi IA. Do Statins Increase the Risk of Esophageal Conditions? Findings from Four Propensity Score-Matched Analyses. Clinical drug investigation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29081029
  9. Waldeyer C, Seiffert M, Staebe N et al. Lipid Management After First Diagnosis of Coronary Artery Disease: Contemporary Results From an Observational Cohort Study. Clinical therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29103665
  10. Thompson GR, Blom DJ, Marais AD et al. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29106543
  11. Vaidean GD, Manczuk M, Vansal SS, Griffith J. The cholesterol-lowering effect of statins is potentiated by whole grains intake. The Polish Norwegian Study (PONS). Eur J Intern Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29137927
  12. Markovitz AA, Holleman RG, Hofer TP et al. Effects of Guideline and Formulary Changes on Statin Prescribing in the Veterans Affairs. Health services research 2017; 52:1996-2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29130272
  13. Wakabayashi K, Ikeda N, Kajimoto K et al. Trends and predictors of non-cardiovascular death in patients hospitalized for acute heart failure. Int J Cardiol 2018; 250:164-170. http://www.ncbi.nlm.nih.gov/pubmed/?term=29169753
  14. Singh A, Collins BL, Gupta A et al. Cardiovascular Risk and Statin Eligibility of Young Adults After an Myocardial Infarction: Partners YOUNG-MI Registry. J Am Coll Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29141201
  15. Cho J, Park IB, Lee K et al. Statin has more protective effects in AMI patients with higher plasma BNP or NT-proBNP level, but not with lower left ventricular ejection fraction. J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29158023
  16. Lee PJ, Modha K, Chua T et al. Association of Statins With Decreased Acute Pancreatitis Severity: A Propensity Score Analysis. Journal of clinical gastroenterology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29095423
  17. Brennan MB, Huang ES, Lobo JM et al. Longitudinal trends and predictors of statin use among patients with diabetes. Journal of diabetes and its complications 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29107453
  18. Kim G, Jang SY, Nam CM, Kang ES. Statin use and the risk of hepatocellular carcinoma in patients at high risk: a nationwide nested case-control study. J Hepatol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29107150
  19. Brar S, Ye F, James M et al. Statin Use and Survival After Acute Kidney Injury. Kidney international reports 2016; 1:279-287. http://www.ncbi.nlm.nih.gov/pubmed/?term=29142930
  20. Sun D, Li S, Zhao X et al. Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: a case control study. Metabolism 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29129821
  21. Al-Rasheed NM, Al-Rasheed NM, Hasan IH et al. Simvastatin Ameliorates Diabetic Cardiomyopathy by Attenuating Oxidative Stress and Inflammation in Rats. Oxidative medicine and cellular longevity 2017; 2017:1092015. http://www.ncbi.nlm.nih.gov/pubmed/?term=29138670
  22. Lucas JE, Bazemore TC, Alo C et al. An electronic health record based model predicts statin adherence, LDL cholesterol, and cardiovascular disease in the United States Military Health System. PLoS One 2017; 12:e0187809. http://www.ncbi.nlm.nih.gov/pubmed/?term=29155848
  23. Justo D, Tchernichovsky M, Kremer A et al. Gender differences in mortality among statin users aged 80 years or more. Zeitschrift fur Gerontologie und Geriatrie 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29116376

Renal Disease

  1. Zavidic T, Lodeta B, Lovrinic D. [USE OF STATINS IN PATIENTS WITH CHRONIC KIDNEY DISEASE TO PREVENT CARDIOVASCULAR DISEASE]. Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti 2016; 70:301-307. http://www.ncbi.nlm.nih.gov/pubmed/?term=29087163
  2. Ercan E. Statin treatment in dialysis patients after acute myocardial infarction improves overall mortality. Atherosclerosis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29111224
  3. Minami Y, Wang Z, Aguirre AD et al. Clinical Predictors for Lack of Favorable Vascular Response to Statin Therapy in Patients With Coronary Artery Disease: A Serial Optical Coherence Tomography Study. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=29092845
  4. Wang Y, Zhu S, Du R et al. Statin initiation and renal outcomes following isolated coronary artery bypass grafting: a meta-analysis. J Cardiovasc Surg (Torino) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29145723
  5. Storey BC, Staplin N, Haynes R et al. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney international 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29146277
  6. Brar S, Ye F, James M et al. Statin Use and Survival After Acute Kidney Injury. Kidney international reports 2016; 1:279-287. http://www.ncbi.nlm.nih.gov/pubmed/?term=29142930
  7. Saeed A, Amin VHM, Alireza M et al. Evaluation of the Effect of Statins on Post-Surgical Patients with Acute Kidney Injury. Maedica 2017; 12:95-100. http://www.ncbi.nlm.nih.gov/pubmed/?term=29090028
  8. Nahar D. Prophylactic Management of Contrast-Induced Acute Kidney Injury in High-Risk Patients. Nephrology nursing journal : journal of the American Nephrology Nurses' Association 2017; 44:244-249. http://www.ncbi.nlm.nih.gov/pubmed/?term=29165956

Reviews

  1. Zavidic T, Lodeta B, Lovrinic D. [USE OF STATINS IN PATIENTS WITH CHRONIC KIDNEY DISEASE TO PREVENT CARDIOVASCULAR DISEASE]. Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti 2016; 70:301-307. http://www.ncbi.nlm.nih.gov/pubmed/?term=29087163
  2. Ercan E. Statin treatment in dialysis patients after acute myocardial infarction improves overall mortality. Atherosclerosis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29111224
  3. Minami Y, Wang Z, Aguirre AD et al. Clinical Predictors for Lack of Favorable Vascular Response to Statin Therapy in Patients With Coronary Artery Disease: A Serial Optical Coherence Tomography Study. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=29092845
  4. Wang Y, Zhu S, Du R et al. Statin initiation and renal outcomes following isolated coronary artery bypass grafting: a meta-analysis. J Cardiovasc Surg (Torino) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29145723
  5. Storey BC, Staplin N, Haynes R et al. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney international 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29146277
  6. Brar S, Ye F, James M et al. Statin Use and Survival After Acute Kidney Injury. Kidney international reports 2016; 1:279-287. http://www.ncbi.nlm.nih.gov/pubmed/?term=29142930
  7. Saeed A, Amin VHM, Alireza M et al. Evaluation of the Effect of Statins on Post-Surgical Patients with Acute Kidney Injury. Maedica 2017; 12:95-100. http://www.ncbi.nlm.nih.gov/pubmed/?term=29090028
  8. Nahar D. Prophylactic Management of Contrast-Induced Acute Kidney Injury in High-Risk Patients. Nephrology nursing journal : journal of the American Nephrology Nurses' Association 2017; 44:244-249. http://www.ncbi.nlm.nih.gov/pubmed/?term=29165956

Safety and side effects

  1. Mrotzek SM, Rassaf T, Totzeck M. Ticagrelor Leads to Statin-Induced Rhabdomyolysis: A Case Report. Am J Case Rep 2017; 18:1238-1241. http://www.ncbi.nlm.nih.gov/pubmed/?term=29167415
  2. Elgendy AY, Elgendy IY, Mahmoud AN et al. Statin Use in Men and New Onset of Erectile Dysfunction: a Systematic Review and Meta-Analysis. Am J Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29146233
  3. Fischer S, Julius U. Management of patients with statin intolerance. Atherosclerosis. Supplements 2017; 30:33-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=29096858
  4. Stefanutti C, Mazza F, Mesce D et al. Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: A clinical study. Atherosclerosis. Supplements 2017; 30:86-91. http://www.ncbi.nlm.nih.gov/pubmed/?term=29096866
  5. Diamond D, Kendrick M, Mascitelli L. Exaggerated report of benefits in a flawed long term statin treatment study. Bmj 2017; 359:j4915. http://www.ncbi.nlm.nih.gov/pubmed/?term=29089296
  6. Ravnskov U, Okuyama H, Sultan S. Serious bias in 20 year follow-up study of statin trial. Bmj 2017; 359:j4906. http://www.ncbi.nlm.nih.gov/pubmed/?term=29089361
  7. Correction: Statin use and risk of developing diabetes: results from the Diabetes Prevention Program. BMJ open diabetes research & care 2017; 5:e000438corr000431. http://www.ncbi.nlm.nih.gov/pubmed/?term=29119974
  8. Crandall JP, Mather K, Rajpathak SN et al. Statin use and risk of developing diabetes: results from the Diabetes Prevention Program. BMJ open diabetes research & care 2017; 5:e000438. http://www.ncbi.nlm.nih.gov/pubmed/?term=29081977
  9. Patoulias D, Michailidis T, Papatolios T et al. Rhabdomyolysis Induced by Coadministration of Fusidic Acid and Atorvastatin: A Case Report and Comprehensive Review of the Literature. Case Rep Nephrol 2017; 2017:2187264. http://www.ncbi.nlm.nih.gov/pubmed/?term=29119029
  10. Smith I, Schmidt R, Halm EA, Mansi IA. Do Statins Increase the Risk of Esophageal Conditions? Findings from Four Propensity Score-Matched Analyses. Clinical drug investigation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29081029
  11. Tshongo Muhindo C, Ahn SA, Rousseau MF et al. Efficacy and safety of a combination of red yeast rice and olive extract in hypercholesterolemic patients with and without statin-associated myalgia. Complementary therapies in medicine 2017; 35:140-144. http://www.ncbi.nlm.nih.gov/pubmed/?term=29154060
  12. Samuel G, Atanda AC, Onyemeh A et al. A Unique Case of Drug Interaction between Ticagrelor and Statin Leading to Acute Renal Failure. Cureus 2017; 9:e1633. http://www.ncbi.nlm.nih.gov/pubmed/?term=29104841
  13. Krysiak R, Szkrobka W, Okopien B. The Effect of Hypolipidemic Agents on Thyroid Autoimmunity in Women with Hashimoto's Thyroiditis Treated with Levothyroxine and Selenomethionine. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29117614
  14. Song M, Chen FF, Li YH et al. Trimetazidine restores the positive adaptation to exercise training by mitigating statin-induced skeletal muscle injury. Journal of cachexia, sarcopenia and muscle 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29152896
  15. Beavers JC. Elevated Creatine Kinase due to Potential Drug Interaction With Ticagrelor and Atorvastatin. Journal of pharmacy practice 2017:897190017740282. http://www.ncbi.nlm.nih.gov/pubmed/?term=29096571
  16. Giugliano RP, Keech A, Murphy SA et al. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29117276
  17. Maki K, Diwadkar-Navsariwala V, Kramer MW. Statin use and risk for type 2 diabetes: what clinicians should know. Postgraduate medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29139315
  18. Bonnet F. [Should statin therapy be discontinued in the elderly?]. La Revue de medecine interne / fondee ... par la Societe nationale francaise de medecine interne 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29157754

Stroke and CNS

  1. Krafcik BM, Farber A, Eberhardt RT et al. Preoperative antiplatelet and statin use does not affect outcomes after carotid endarterectomy. Annals of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29100876
  2. Hwong WY, Abdul Aziz Z, Sidek NN et al. Prescription of secondary preventive drugs after ischemic stroke: results from the Malaysian National Stroke Registry. BMC Neurol 2017; 17:203. http://www.ncbi.nlm.nih.gov/pubmed/?term=29169331
  3. Mizobe T, Nakamura M, Motooka Y et al. Impact of Additional Lipid-Lowering Therapy on New Ischemic Lesions of Diffusion-Weighted Imaging in Carotid Artery Stenting. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29103862
  4. Marques NF, Castro AA, Mancini G et al. Atorvastatin Prevents Early Oxidative Events and Modulates Inflammatory Mediators in the Striatum Following Intranasal 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Administration in Rats. Neurotox Res 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29164519
  5. Al-Rasheed NM, Al-Rasheed NM, Hasan IH et al. Simvastatin Ameliorates Diabetic Cardiomyopathy by Attenuating Oxidative Stress and Inflammation in Rats. Oxidative medicine and cellular longevity 2017; 2017:1092015. http://www.ncbi.nlm.nih.gov/pubmed/?term=29138670
  6. Nomura I, Kishi T, Ikuta T, Iwata N. Statin add-on therapy in the antipsychotic treatment of schizophrenia: A meta-analysis. Psychiatry research 2017; 260:41-47. http://www.ncbi.nlm.nih.gov/pubmed/?term=29172097
  7. Ganz P, Amarenco P, Goldstein LB et al. Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks: Results of an Analysis of 13 Biomarkers From the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. Stroke 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29114094

Trials

  1. Madi M, Kassem A. Topical simvastatin gel as a novel therapeutic modality for palatal donor site wound healing following free gingival graft procedure. Acta odontologica Scandinavica 2017:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=29145771
  2. Stefanutti C, Mazza F, Mesce D et al. Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: A clinical study. Atherosclerosis. Supplements 2017; 30:86-91. http://www.ncbi.nlm.nih.gov/pubmed/?term=29096866
  3. Kim KM, Jung KY, Yun HM et al. Effect of rosuvastatin on fasting and postprandial endothelial biomarker levels and microvascular reactivity in patients with type 2 diabetes and dyslipidemia: a preliminary report. Cardiovascular diabetology 2017; 16:146. http://www.ncbi.nlm.nih.gov/pubmed/?term=29121934
  4. Bonaca MP, Nault P, Giugliano RP et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29133605
  5. Burstein B, Altobelli KK, Williams K et al. Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey. Circulation 2017; 136:1860-1862. http://www.ncbi.nlm.nih.gov/pubmed/?term=29109198
  6. Lee HY, Kim SY, Choi KJ et al. A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia. Clinical therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29150250
  7. Szczepanik A, Hulbert A, Lee HJ et al. Effect of HMG CoA reductase inhibitors on the development of chronic lung allograft dysfunction. Clinical transplantation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29151274
  8. Tshongo Muhindo C, Ahn SA, Rousseau MF et al. Efficacy and safety of a combination of red yeast rice and olive extract in hypercholesterolemic patients with and without statin-associated myalgia. Complementary therapies in medicine 2017; 35:140-144. http://www.ncbi.nlm.nih.gov/pubmed/?term=29154060
  9. Aktas S, Ucak S, Kurt F et al. Evaluation of protein c and protein s levels in patients with diabetes mellitus receiving therapy with statins and ace inhibitors or angiotensin II receptor blockers. Diabetes Res Clin Pract 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29155121
  10. Bishnu S, Ahammed SM, Sarkar A et al. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study. European journal of gastroenterology & hepatology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29099421
  11. Krysiak R, Szkrobka W, Okopien B. The Effect of Hypolipidemic Agents on Thyroid Autoimmunity in Women with Hashimoto's Thyroiditis Treated with Levothyroxine and Selenomethionine. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29117614
  12. Singh RK, Agarwal V, Baronia AK et al. The Effects of Atorvastatin on Inflammatory Responses and Mortality in Septic Shock: A Single-center, Randomized Controlled Trial. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine 2017; 21:646-654. http://www.ncbi.nlm.nih.gov/pubmed/?term=29142375
  13. Kang WY, Seong SJ, Ohk B et al. Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects. International journal of clinical pharmacology and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29162214
  14. Kato ET, Cannon CP, Blazing MA et al. Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=29151034
  15. Minami Y, Wang Z, Aguirre AD et al. Clinical Predictors for Lack of Favorable Vascular Response to Statin Therapy in Patients With Coronary Artery Disease: A Serial Optical Coherence Tomography Study. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=29092845
  16. Spannella F, Giulietti F, Balietti P et al. Renin-Angiotensin System Blockers and Statins Are Associated With Lower In-Hospital Mortality in Very Elderly Hypertensives. Journal of the American Medical Directors Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29128438
  17. Wada S, Koga M, Toyoda K et al. Factors Associated with Intima-Media Complex Thickness of the Common Carotid Artery in Japanese Noncardioembolic Stroke Patients with Hyperlipidemia: The J-STARS Echo Study. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29118311
  18. Sandesara PB, Ramjee V, Ghasemzadeh N et al. Circulating progenitor cells in patients with familial hypercholesterolemia. Journal of clinical apheresis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29114919
  19. Arsenault BJ, Petrides F, Tabet F et al. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29103916
  20. Koh KK, Nam CW, Chao TH et al. A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT). J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29153823
  21. Mizobe T, Nakamura M, Motooka Y et al. Impact of Additional Lipid-Lowering Therapy on New Ischemic Lesions of Diffusion-Weighted Imaging in Carotid Artery Stenting. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29103862
  22. Giugliano RP, Keech A, Murphy SA et al. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29117276
  23. Storey BC, Staplin N, Haynes R et al. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney international 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29146277
  24. Saeed A, Amin VHM, Alireza M et al. Evaluation of the Effect of Statins on Post-Surgical Patients with Acute Kidney Injury. Maedica 2017; 12:95-100. http://www.ncbi.nlm.nih.gov/pubmed/?term=29090028
  25. Zheng W, Zhang YJ, Bu XT et al. LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China: Subgroup analysis of the dyslipidemia international study of China (DYSIS-China). Medicine (Baltimore) 2017; 96:e8555. http://www.ncbi.nlm.nih.gov/pubmed/?term=29145263
  26. Auckle R, Su B, Li H et al. Familial hypercholesterolemia in Chinese patients with premature ST-segment-elevation myocardial infarction: Prevalence, lipid management and 1-year follow-up. PLoS One 2017; 12:e0186815. http://www.ncbi.nlm.nih.gov/pubmed/?term=29088271
  27. Nomura I, Kishi T, Ikuta T, Iwata N. Statin add-on therapy in the antipsychotic treatment of schizophrenia: A meta-analysis. Psychiatry research 2017; 260:41-47. http://www.ncbi.nlm.nih.gov/pubmed/?term=29172097
  28. Ganz P, Amarenco P, Goldstein LB et al. Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks: Results of an Analysis of 13 Biomarkers From the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. Stroke 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29114094
  29. Nishio T, Taura K, Nakamura N et al. Impact of statin use on the prognosis of patients with hepatocellular carcinoma undergoing liver resection: a subgroup analysis of patients without chronic hepatitis viral infection. Surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29167018 

Women and elderly

  1. Gulliford M, Ravindrarajah R, Hamada S et al. Inception and deprescribing of statins in people aged over 80 years: cohort study. Age and ageing 2017; 46:1001-1005. http://www.ncbi.nlm.nih.gov/pubmed/?term=29088364
  2. Todd JV, Cole SR, Wohl DA et al. Underutilization of Statins When Indicated in HIV-Seropositive and Seronegative Women. AIDS patient care and STDs 2017; 31:447-454. http://www.ncbi.nlm.nih.gov/pubmed/?term=29087746
  3. Eindhoven DC, Hilt AD, Zwaan TC et al. Age and gender differences in medical adherence after myocardial infarction: Women do not receive optimal treatment - The Netherlands claims database. Eur J Prev Cardiol 2017:2047487317744363. http://www.ncbi.nlm.nih.gov/pubmed/?term=29164916
  4. Spannella F, Giulietti F, Balietti P et al. Renin-Angiotensin System Blockers and Statins Are Associated With Lower In-Hospital Mortality in Very Elderly Hypertensives. Journal of the American Medical Directors Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29128438
  5. Xie S, Zhou J. Effect of statins and the clinical nursing characteristics in patients with acute myocardial infarction. Pak J Pharm Sci 2017; 30:1843-1849. http://www.ncbi.nlm.nih.gov/pubmed/?term=29084656
  6. Bonnet F. [Should statin therapy be discontinued in the elderly?]. La Revue de medecine interne / fondee ... par la Societe nationale francaise de medecine interne 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29157754
  7. Justo D, Tchernichovsky M, Kremer A et al. Gender differences in mortality among statin users aged 80 years or more. Zeitschrift fur Gerontologie und Geriatrie 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29116376

 
 

Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.